ABL Bio Inc.

KOSDAQ 298380.KQ

ABL Bio Inc. Revenue for the year ending December 31, 2023: USD 50.34 M

ABL Bio Inc. Revenue is USD 50.34 M for the year ending December 31, 2023, a -5.32% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

ABL Bio Inc. Revenue for the year ending December 31, 2022 was USD 53.17 M, a 1,091.31% change year over year.
ABL Bio Inc. Revenue for the year ending December 31, 2021 was USD 4.46 M, a -40.01% change year over year.
ABL Bio Inc. Revenue for the year ending December 31, 2020 was USD 7.44 M, a 116.36% change year over year.
ABL Bio Inc. Revenue for the year ending December 31, 2019 was USD 3.44 M, a 205.77% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

KOSDAQ: 298380.KQ

ABL Bio Inc.

CEO	Dr. Sang Hoon Lee Ph.D.
IPO Date	Dec. 19, 2018
Location	South Korea
Headquarters	16 Daewangpangyo-Ro 712 Beon-Gil
Employees	102
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.

Key trends

Past 5 years